Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis

NCT03395704 is registered in ClinicalTrials.gov with La Jolla Pharmaceutical Company as lead sponsor.

NCT NCT03395704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03395704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Center, Randomized, Placebo Controlled, Single-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
Lead sponsor
La Jolla Pharmaceutical Company
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2017
Completion date
October 28, 2019
Enrollment
70 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemochromatosis